Chiauzzi, Emil
Williams, Andre
Mariano, Timothy Y.
Pajarito, Sarah
Robinson, Athena
Kirvin-Quamme, Andrew
Forman-Hoffman, Valerie
Article History
Received: 17 January 2023
Accepted: 17 January 2024
First Online: 30 January 2024
Declarations
:
: This study was conducted in accordance with the principles of the Declaration of Helsinki. This study and all study procedures were approved by the WIRB-Copernicus IRB Group (WCG) institutional review board [Protocol #20216751] on January 20, 2022. All participants provided informed consent.
: Not applicable.
: Authors EC, AW, TYM, SP, AR, AKQ, and VFH were employees of Woebot Health at the time of submission. TYM is an employee of the US Department of Veterans Affairs. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.
: Woebot for Mood & Anxiety (W-MA-02) is an investigational medical device. It has not been evaluated, cleared, or approved by the FDA.